Developer docs
API playgroundTry for free, no card

Search company profiles

Theratechnologies

Full company profile

uuid0000sfl

Namestring
Theratechnologies
Legal namestring
Theratechnologies Inc.
Websiteurl
theratech.com
Company typeenum
Public
Founded yearint
1993
Descriptiontext

Theratechnologies is a commercial-stage biopharmaceutical company headquartered in Montreal, Quebec, that develops and markets specialty prescription drugs focused on unmet medical needs in HIV. Originally founded in 1993, the company transitioned from an outsourced model to in-house commercial operations in 2014 and currently markets three FDA-approved prescription products in the United States—Trogarzo (ibalizumab-uiyk), EGRIFTA WR (tesamorelin F8) approved March 2025, and EGRIFTA SV (tesamorelin F4)—together with Mytesi in its HIV portfolio. The company also holds licensing rights from Ionis to olezarsen and donidalorsen for potential future commercialization in rare diseases.

EGRIFTA WR is patent-protected in the United States until 2033 and represents the only FDA-approved treatment for excess abdominal fat in HIV-associated lipodystrophy; its predecessor EGRIFTA SV is being systematically transitioned out by the company. Trogarzo, a long-acting monoclonal antibody that binds CD4 T-cell domain 2 to block viral entry, was the first new HIV drug class approved in more than ten years and the first long-acting HIV treatment cleared by the FDA, and received FDA approval for IV push administration in October 2022. Commercial operations are concentrated in the United States, where field-sales teams target HIV-treating physicians, McKesson serves as primary distributor, and dispensing runs through a specialty pharmacy network supported by the Thera Patient Support patient-navigator program.

Theratechnologies generated $19.0 million in Q1 2025 revenue (+17.2% YoY), with full-year 2025 pre-acquisition guidance of $80–83 million later withdrawn. The capital structure was materially reshaped first by an October 2023 US$25 million public offering plus concurrent Investissement Québec private placement, and then by up to $75 million in new credit facilities from TD Bank and Investissement Québec in December 2024. In September 2025, CB Biotechnology, an affiliate of Future Pak, completed an acquisition with US$254 million total consideration, taking the company private and delisting it from TSX and NASDAQ.

Short descriptiontext

Theratechnologies is a Canada-headquartered commercial-stage biopharmaceutical company that markets three FDA-approved HIV drugs in the United States—Trogarzo, EGRIFTA WR, and EGRIFTA SV—targeting multidrug-resistant HIV-1 and HIV-associated lipodystrophy through specialty pharmacy distribution, and was acquired by Future Pak in September 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HIV therapeutics, biopharmaceutical products, specialty pharmaceuticals, monoclonal antibody therapy, HIV lipodystrophy treatment
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product sales (EGRIFTA SV/WR and Trogarzo)
TypeSubscription Recurring
Description

Theratechnologies generates revenue through the sale of prescription pharmaceutical products. EGRIFTA SV net sales were $13.9M in Q1 2025 (44.8% YoY increase) and $11.1M in Q2 2025. Trogarzo net sales were $5.2M in Q1 2025 (22.4% decrease) and $6.6M in Q2 2025 (13.4% increase). Q1 2025 total revenue was $19.0M representing 17% growth YoY. Full year 2025 guidance was $80-83M revenue.

theratech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Trogarzo
Description

Long-acting monoclonal antibody for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1

theratech.com
+3 more records
Core offering1 text field

Theratechnologies is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved prescription therapeutics for people living with HIV. Its marketed portfolio includes Trogarzo (ibalizumab-uiyk) for multi-drug resistant HIV-1, EGRIFTA SV and EGRIFTA WR (tesamorelin) for HIV-associated lipodystrophy, and Mytesi (crofelemer) for HIV-related non-infectious diarrhea. The company engages in proprietary drug discovery, formulation science, and specialty commercialization focused on underserved HIV treatment niches.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • EGRIFTA SV sales increased 44.8% YoY in Q1 2025 to $13.9M
+3 more records
Product overview1 text field

Theratechnologies is a commercial-stage biopharmaceutical company that commercializes three FDA-approved prescription products for people with HIV in the United States: Trogarzo® (ibalizumab-uiyk), a long-acting monoclonal antibody for heavily treatment-experienced patients with multidrug resistant HIV; EGRIFTA WR™ (tesamorelin F8), the newest formulation approved in March 2025 for reducing excess visceral abdominal fat in HIV patients with lipodystrophy; and EGRIFTA SV® (tesamorelin F4), the daily-reconstituted predecessor formulation being gradually replaced by EGRIFTA WR™. The company also markets Mytesi® as part of its HIV portfolio. The products focus on addressing unmet medical needs in HIV treatment and HIV-associated conditions like lipodystrophy.

Product and service1 record
1Trogarzo (ibalizumab-uiyk)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-25
Description

Future Pak (through its affiliate CB Biotechnology) completed acquisition of Theratechnologies for US$254 million total consideration on September 25, 2025. Future Pak is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products founded in 1977 and headquartered in Wixom, Michigan.

2McKesson
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

McKesson serves as the primary wholesale distributor for Theratechnologies' pharmaceutical products (EGRIFTA SV/WR and Trogarzo) in the United States. Distribution resumed in February 2025 following supply disruption resolution.

theratech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ViiV Healthcare is the leading dedicated HIV specialty pharmaceutical company (owned by GSK, Pfizer and Shionogi). It directly competes with Theratechnologies in HIV therapeutics and long-acting HIV treatment development, making it the closest comparable in category, patient base, and commercial model.

2Nabriva Therapeutics
TypeEmerging player
Description

Nabriva is a small specialty anti-infectives company focused on niche infectious-disease indications. While not a direct HIV peer, its specialty infectious-disease model and small-scale commercial footprint are operationally comparable.

TypeDirect peer
Description

TaiMed Biologics is the originator/developer of ibalizumab (Trogarzo) and a specialty HIV-focused biotechnology company. It is a direct peer in HIV drug development with a closely aligned technology base and target indication.

TypeBroad incumbent
Description

Bausch Health operates a specialty pharmaceutical division with focus areas including infectious disease and rare disorders. Its specialty pharma model and broad portfolio are comparable to Theratechnologies' commercial-stage specialty pharma positioning.

TypeEmerging player
Description

Brii Biosciences is a clinical-stage infectious-disease biopharma focused on HIV cure and treatment in partnership with major players. It represents an emerging player overlapping with Theratechnologies' HIV therapeutic focus.

TypeBroad incumbent
Description

Janssen markets long-acting HIV regimens (cabotegravir/rilpivirine) that overlap with the patient segments addressed by Trogarzo. As a large incumbent in infectious disease and HIV, it is a critical competitor to Theratechnologies' niche HIV franchise.

TypeBroad incumbent
Description

Ionis is Theratechnologies' licensor for olezarsen and donidalorsen and operates as a specialty RNA-targeting biopharmaceutical company. It is comparable in therapeutic focus (rare/specialty diseases) and as a development partner shaping Theratechnologies' pipeline.

TypeBroad incumbent
Description

Merck is a major HIV franchise participant (Dovato/islatravir programs, doravirine) and a broad biopharmaceutical incumbent. Its investment in long-acting HIV and infectious disease therapies places it in overlapping competitive and licensing territory with Theratechnologies.

TypeBroad incumbent
Description

BioMarin is a rare-disease specialty biopharmaceutical company commercializing drugs through specialty pharmacy channels and physician networks. Its operating model—small patient populations, specialty distribution, and high-touch patient services—mirrors Theratechnologies' U.S. commercial approach.

TypeBroad incumbent
Description

Gilead is the dominant broad HIV franchise (Biktarvy, Descovy, Sunlenca) and a major infectious-disease biopharmaceutical incumbent. Although broader than Theratechnologies, it competes in the same patient population and shapes the standard-of-care regimen against which EGRIFTA and Trogarzo are positioned.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Theratechnologies

Biopharmaceuticalstheratech.com

Theratechnologies is a Canada-headquartered commercial-stage biopharmaceutical company that markets three FDA-approved HIV drugs in the United States—Trogarzo, EGRIFTA WR, and EGRIFTA SV—targeting multidrug-resistant HIV-1 and HIV-associated lipodystrophy through specialty pharmacy distribution, and was acquired by Future Pak in September 2025.

What Theratechnologies does

Theratechnologies is a commercial-stage biopharmaceutical company headquartered in Montreal, Quebec, that develops and markets specialty prescription drugs focused on unmet medical needs in HIV. Originally founded in 1993, the company transitioned from an outsourced model to in-house commercial operations in 2014 and currently markets three FDA-approved prescription products in the United States—Trogarzo (ibalizumab-uiyk), EGRIFTA WR (tesamorelin F8) approved March 2025, and EGRIFTA SV (tesamorelin F4)—together with Mytesi in its HIV portfolio. The company also holds licensing rights from Ionis to olezarsen and donidalorsen for potential future commercialization in rare diseases.

EGRIFTA WR is patent-protected in the United States until 2033 and represents the only FDA-approved treatment for excess abdominal fat in HIV-associated lipodystrophy; its predecessor EGRIFTA SV is being systematically transitioned out by the company. Trogarzo, a long-acting monoclonal antibody that binds CD4 T-cell domain 2 to block viral entry, was the first new HIV drug class approved in more than ten years and the first long-acting HIV treatment cleared by the FDA, and received FDA approval for IV push administration in October 2022. Commercial operations are concentrated in the United States, where field-sales teams target HIV-treating physicians, McKesson serves as primary distributor, and dispensing runs through a specialty pharmacy network supported by the Thera Patient Support patient-navigator program.

Theratechnologies generated $19.0 million in Q1 2025 revenue (+17.2% YoY), with full-year 2025 pre-acquisition guidance of $80–83 million later withdrawn. The capital structure was materially reshaped first by an October 2023 US$25 million public offering plus concurrent Investissement Québec private placement, and then by up to $75 million in new credit facilities from TD Bank and Investissement Québec in December 2024. In September 2025, CB Biotechnology, an affiliate of Future Pak, completed an acquisition with US$254 million total consideration, taking the company private and delisting it from TSX and NASDAQ.

Theratechnologies firmographics

Firmographics
Name
Theratechnologies
Legal name
Theratechnologies Inc.
Website
https://theratech.com
Company type
Public
Founded year
1993
Operating status
Acquired
Headcount range
51–100 employees
Short description
Theratechnologies is a Canada-headquartered commercial-stage biopharmaceutical company that markets three FDA-approved HIV drugs in the United States—Trogarzo, EGRIFTA WR, and EGRIFTA SV—targeting multidrug-resistant HIV-1 and HIV-associated lipodystrophy through specialty pharmacy distribution, and was acquired by Future Pak in September 2025.
Ownership category
akta.pro rank

Theratechnologies industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • HIV therapeutics
  • Biopharmaceutical products
  • Specialty pharmaceuticals
  • Monoclonal antibody therapy
  • HIV lipodystrophy treatment

Where Theratechnologies is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Theratechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Product sales (EGRIFTA SV/WR and Trogarzo): Theratechnologies generates revenue through the sale of prescription pharmaceutical products. EGRIFTA SV net sales were $13.9M in Q1 2025 (44.8% YoY increase) and $11.1M in Q2 2025. Trogarzo net sales were $5.2M in Q1 2025 (22.4% decrease) and $6.6M in Q2 2025 (13.4% increase). Q1 2025 total revenue was $19.0M representing 17% growth YoY. Full year 2025 guidance was $80-83M revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Theratechnologies product offering

Product offering

Core offering

Theratechnologies is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved prescription therapeutics for people living with HIV. Its marketed portfolio includes Trogarzo (ibalizumab-uiyk) for multi-drug resistant HIV-1, EGRIFTA SV and EGRIFTA WR (tesamorelin) for HIV-associated lipodystrophy, and Mytesi (crofelemer) for HIV-related non-infectious diarrhea. The company engages in proprietary drug discovery, formulation science, and specialty commercialization focused on underserved HIV treatment niches.

Product overview

Theratechnologies is a commercial-stage biopharmaceutical company that commercializes three FDA-approved prescription products for people with HIV in the United States: Trogarzo® (ibalizumab-uiyk), a long-acting monoclonal antibody for heavily treatment-experienced patients with multidrug resistant HIV; EGRIFTA WR™ (tesamorelin F8), the newest formulation approved in March 2025 for reducing excess visceral abdominal fat in HIV patients with lipodystrophy; and EGRIFTA SV® (tesamorelin F4), the daily-reconstituted predecessor formulation being gradually replaced by EGRIFTA WR™. The company also markets Mytesi® as part of its HIV portfolio. The products focus on addressing unmet medical needs in HIV treatment and HIV-associated conditions like lipodystrophy.

Differentiator

Problem solved

Functional benefit

Brands

  • Trogarzo: Long-acting monoclonal antibody for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1
  • EGRIFTA SV
  • EGRIFTA WR
  • Mytesi

Products and services

  • Trogarzo (ibalizumab-uiyk)

Quantifiable outcome

  • EGRIFTA SV sales increased 44.8% YoY in Q1 2025 to $13.9M
  • +3 more outcomes

Companies that use Theratechnologies

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Theratechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Theratechnologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Future Pak / CB BiotechnologyflagshipStrategic or Co-development Partner · 25 September 2025Future Pak (through its affiliate CB Biotechnology) completed acquisition of Theratechnologies for US$254 million total consideration on September 25, 2025. Future Pak is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products founded in 1977 and headquartered in Wixom, Michigan.
  • McKessoncoreChannel Partner/ Reseller/ DistributorMcKesson serves as the primary wholesale distributor for Theratechnologies' pharmaceutical products (EGRIFTA SV/WR and Trogarzo) in the United States. Distribution resumed in February 2025 following supply disruption resolution.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Theratechnologies competitors and assessment

Company assessment

Direct peers

  • ViiV Healthcare: ViiV Healthcare is the leading dedicated HIV specialty pharmaceutical company (owned by GSK, Pfizer and Shionogi). It directly competes with Theratechnologies in HIV therapeutics and long-acting HIV treatment development, making it the closest comparable in category, patient base, and commercial model.
  • TaiMed Biologics: TaiMed Biologics is the originator/developer of ibalizumab (Trogarzo) and a specialty HIV-focused biotechnology company. It is a direct peer in HIV drug development with a closely aligned technology base and target indication.

Emerging players

  • Nabriva Therapeutics: Nabriva is a small specialty anti-infectives company focused on niche infectious-disease indications. While not a direct HIV peer, its specialty infectious-disease model and small-scale commercial footprint are operationally comparable.
  • Brii Biosciences: Brii Biosciences is a clinical-stage infectious-disease biopharma focused on HIV cure and treatment in partnership with major players. It represents an emerging player overlapping with Theratechnologies' HIV therapeutic focus.

Broad incumbents

  • Bausch Health: Bausch Health operates a specialty pharmaceutical division with focus areas including infectious disease and rare disorders. Its specialty pharma model and broad portfolio are comparable to Theratechnologies' commercial-stage specialty pharma positioning.
  • Johnson & Johnson (Janssen): Janssen markets long-acting HIV regimens (cabotegravir/rilpivirine) that overlap with the patient segments addressed by Trogarzo. As a large incumbent in infectious disease and HIV, it is a critical competitor to Theratechnologies' niche HIV franchise.
  • Ionis Pharmaceuticals: Ionis is Theratechnologies' licensor for olezarsen and donidalorsen and operates as a specialty RNA-targeting biopharmaceutical company. It is comparable in therapeutic focus (rare/specialty diseases) and as a development partner shaping Theratechnologies' pipeline.
  • Merck & Co. Merck is a major HIV franchise participant (Dovato/islatravir programs, doravirine) and a broad biopharmaceutical incumbent. Its investment in long-acting HIV and infectious disease therapies places it in overlapping competitive and licensing territory with Theratechnologies.
  • BioMarin Pharmaceutical: BioMarin is a rare-disease specialty biopharmaceutical company commercializing drugs through specialty pharmacy channels and physician networks. Its operating model—small patient populations, specialty distribution, and high-touch patient services—mirrors Theratechnologies' U.S. commercial approach.
  • Gilead Sciences: Gilead is the dominant broad HIV franchise (Biktarvy, Descovy, Sunlenca) and a major infectious-disease biopharmaceutical incumbent. Although broader than Theratechnologies, it competes in the same patient population and shapes the standard-of-care regimen against which EGRIFTA and Trogarzo are positioned.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Theratechnologies social profiles

Digital presence

Theratechnologies compliance and trust

Trust signal

Compliance1 record

Theratechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Theratechnologies leadership team

Management profile

Number of profiles

Profiles11 records

Theratechnologies subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Theratechnologies funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Theratechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theratechnologies

What does Theratechnologies do?

Theratechnologies is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved prescription therapeutics for people living with HIV. Its marketed portfolio includes Trogarzo (ibalizumab-uiyk) for multi-drug resistant HIV-1, EGRIFTA SV and EGRIFTA WR (tesamorelin) for HIV-associated lipodystrophy, and Mytesi (crofelemer) for HIV-related non-infectious diarrhea. The company engages in proprietary drug discovery, formulation science, and specialty commercialization focused on underserved HIV treatment niches.

Is Theratechnologies a public or private company?

Theratechnologies is a public company. It is classified as corporate owned and is currently acquired.

When was Theratechnologies founded?

Theratechnologies was founded in 1993. It employs 51 to 100 people.

Where is Theratechnologies based?

Theratechnologies is headquartered in Montreal, Canada, in the North America region.

How does Theratechnologies make money?

One revenue line is on record: product sales (EGRIFTA SV/WR and Trogarzo).

Who are Theratechnologies's main competitors?

Direct peers on record are ViiV Healthcare and TaiMed Biologics. Emerging players are Nabriva Therapeutics and Brii Biosciences. Broad incumbents are Bausch Health, Johnson & Johnson (Janssen), Ionis Pharmaceuticals, Merck & Co., BioMarin Pharmaceutical and Gilead Sciences.

Does Theratechnologies have an API?

No public API is recorded for Theratechnologies.

What industry is Theratechnologies in?

Theratechnologies's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldTheratechnologies (TSE:TH) Shares Cross Above 50 Day Moving Average – Time to Sell?Theratechnologies shares crossed above its 50-day moving average on Tuesday, trading at C$4.47 with a volume of 35,472 shares. The stock is down 4.9% and has a market cap of C$205.53 million. The company operates specialty pharmaceuticals for HIV patients in Canada and the US.WikipediaTesamorelin: Difference between revisionsTesamorelin, sold under the trade name Egrifta SV, is a synthetic growth-hormone-releasing hormone approved in 2010 for treating HIV-associated lipodystrophy. Developed by Canadian company Theratechnologies, it is an N-terminally modified peptide of 44 amino acids plus a trans-3-hexenoic acid group, making it more potent, stable and resistant to dipeptidyl aminopeptidase cleavage than natural GHRH. It stimulates endogenous GH and IGF-1, reducing body fat mainly through lipolysis and triglyceride reduction.Defense WorldTheratechnologies (TSE:TH) Stock Price Crosses Below 200-Day Moving Average – Here’s What HappenedTheratechnologies Inc. stock price fell below its 200-day moving average of C$4.47 during Friday trading, reaching a low of C$4.36. The company operates in the specialty pharmaceutical sector, focusing on HIV treatments in Canada and the United States.Tracxn2026 Investment Bank Profile, Deals and M&ABarclays Investment Bank, founded in 1997 and headquartered in New York City, has facilitated 12 deals as of May 2026, consisting of 9 M&A transactions and 3 funding rounds. The firm's most recent transactions include the $***** Post IPO round for Solaria on April 29, 2026, and the acquisition of Theratechnologies by CB Biotechnology on July 2, 2025. Barclays Investment Bank primarily facilitates Business Acquisition and Series D deals for United States and United Kingdom-based companies, operating with a team of 105 people including 4 partners.ZS AssociatesTheratechnologies pharma analytics case studyMontreal-based Theratechnologies Inc. partnered with ZS to implement the ZAIDYN analytics platform, transitioning from an outsourced commercial model to building internal data and analytics infrastructure for its U.S. pharmaceutical operations. The company successfully unified its commercial data warehouse, created role-based dashboards, and established centralized analytics capabilities for sales, medical affairs, and marketing teams. Three years after the 2021 transformation, Theratechnologies saw the percentage of U.S. territories contributing to year-over-year sales growth rise from 20% to 85%, with improved contract negotiations and daily field insights driving commercial performance.GlobeNewswirePeptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & OutlookResearchAndMarkets.com has published a market report projecting the global Peptide Drug Conjugate (PDC) market to exceed USD 1.5 billion by 2031, with over 14% CAGR growth from 2021-2025, covering approved therapies, clinical trials, proprietary technologies, and competitive landscape. The report identifies oncology as the primary development focus, with over 50 peptide conjugates in clinical trials and 18 proprietary technologies driving innovation in targeted drug delivery. The competitive landscape features both established pharmaceutical companies and emerging biotechnology firms leveraging collaborations and licensing agreements to advance peptide chemistry and linker technologies.Defense WorldTheratechnologies (TSE:TH) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?Theratechnologies Inc.'s share price crossed above its 50-day moving average during trading, reaching C$4.53 intraday high before settling at C$4.47 with a volume of 35,472 shares. The specialty pharmaceutical company has a market cap of C$205.53 million and operates with a debt-to-equity ratio of -156.22. Theratechnologies is a Canada and U.S.-focused company with two approved HIV-related products: EGRIFTA (marketed in both countries) and Trogarzo (approved for commercialization in the United States).McMillan LLPMcMillan Advises Future Pak on its Acquisition of TheratechnologiesFuture Pak completed its acquisition of Theratechnologies on September 25, 2025, through a plan of arrangement involving cash and contingent value rights, with Theratechnologies being de-listed from stock exchanges. McMillan advised Future Pak as lead Canadian counsel in this cross-border transaction. The deal resulted in Theratechnologies ceasing its status as a reporting issuer under Canadian and US securities laws.GlobeNewswireTheratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future PakTheratechnologies announced that ISS and Glass Lewis recommended shareholders vote FOR the proposed acquisition by Future Pak. The deal offers US$3.01 per share in cash plus contingent value rights, with a shareholder meeting set for September 12, 2025.